Search Results 61-70 of 16568 for B cell lymphomas
In B-cell non-Hodgkin's lymphoma, cells other than tumor cells are commonly seen within tumor tissue. These cells include T lymphocytes that seem to be more ...
... lymphomas with CD30 expression that have not responded to treatment or have come back. The subtypes we are studying are Diffuse Large B-Cell Lymphoma (DLBCL) ...
T-cell/histiocyte rich large B-cell lymphoma;; DLBCL associated with chronic inflammation;; Primary cutaneous DLBCL, leg type;; Epstein-Barr virus (EBV) + ...
... cell lymphoma, a subset of B-cell lymphoma. It was also approved in February 2014 for use in CLL, following a study of the agent alone in patients with very ...
Developing the Lymph2Cx genetic test to help guide the diagnosis and treatment of people with diffuse large B-cell lymphoma, the most common type of non- ...
... lymphoma or B-cell acute leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by ...
CD20+Diffuse Large B-Cell Lymphoma. · Ann Arbor stage 3 or 4 or stage 2 with bulky disease · High or high-intermediate disease risk. · No prior anti-lymphoma ...
... B-cell non-Hodgkin lymphoma (NHL), and in previously untreated participants with diffuse large B-cell lymphoma (DLBCL). Participation eligibility.
Although B cells and T cells can give rise to malignancies or lymphomas, T-cell lymphoma is the rarer disease, making up less than 15% of all Non-Hodgkin ...
The purpose of tis study is to evaluate whether adding brentuximab vedotin helps two drugs work better to treat patients with diffuse large B-cell lymphoma ( ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Thanks to generous benefactors, your gift today can have 5X the impact to advance AI innovation at Mayo Clinic.